Tissueform, Inc.
Boulder, CO
- UEI
- H25TERHQ5S68
- CAGE
- 8BFD8
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2147 Kincaid Pl, Boulder, CO 80304, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Sbir phase i: natrugel: next-generation and granular tissue bioinks for 3D bioprinting | National Science Foundation | $274,822 |
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The Regents Of The University Of Colorado | U01AR082845 | $110,000 | |
| The Regents Of The University Of Colorado | U01AR082845 | $110,000 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Regenhu SA | Villaz, FR | 333998 All Other Miscellaneous General Purpose Machinery Manufacturing |
| Materic LLC | Baltimore, MD | 325998 All Other Miscellaneous Chemical Product and Preparation Manufacturing |
| Endomimetics, Inc. | Birmingham, AL | — |
| Insoma Bio, Inc. | Durham, NC | — |
| Epibone, Inc. | New York, NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Tissueform, Inc. is a for-profit, woman-owned small business located in Boulder, Colorado, that specializes in advanced biomaterials and bioengineering technologies. Registered in SAM.gov since May 12, 2019, the company focuses on developing innovative biotechnology solutions, particularly in the realm of 3D bioprinting and regenerative medicine. While the company has not been awarded a federal contract vehicle, it has successfully secured federal grant awards, demonstrating its commitment to cutting-edge scientific research and technological innovation.
Tissueform, Inc. has received a significant National Science Foundation (NSF) Technology, Innovation, and Partnerships SBIR Phase I grant valued at $274,822, aimed at developing a library of human-based bioinks for 3D bioprinting applications. The grant, with a performance period from September 2024 to August 2025, focuses on creating granulated bioinks for tissues such as cartilage, bone, skin, liver, and kidney to advance drug discovery and organ-on-chip models. Additionally, the company has been involved in sub-awards with the University of Colorado Boulder, specifically collaborating on Regenerative Medicine Innovation Projects (RMIP). These sub-awards involve working with Allosource to establish cGMP facilities and produce human-derived Natrulage product lots, with tasks including developing product workflows, conducting mechanical and biological testing, and preparing FDA IDE application documentation. These grants highlight Tissueform's expertise in biomaterial development, cell culture technologies, and advanced manufacturing processes for regenerative medicine applications.
Quick answers
Is Tissueform, Inc. registered in SAM.gov?
Yes. Tissueform, Inc.'s SAM.gov registration is active through February 11, 2027.
What is Tissueform, Inc.'s most recent federal award?
Tissueform, Inc.'s most recent federal grant award is Sbir phase i: natrugel: next-generation and granular tissue bioinks for 3D bioprinting (2423489), from National Science Foundation, on September 1, 2024.
On GovTribe
See Tissueform, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors